The US hematologic malignancies market size was evaluated at USD 2.29 billion in 2024 and is expected to grow around USD 58.2 billion by 2034, registering a CAGR of 38.2% from 2025 to 2034.
The hematologic malignancies market is increasing because of the rise in blood cancers like leukemias, lymphomas, and multiple myelomas. The market has been created for the advanced diagnostic technologies and therapeutic procedures owing to the growing gene-level and molecular-level testing, targeted medicines, and treatments, including CAR-T, among others.
Highlights of the US Hematologic Malignancies Market
- North America dominated the global market in 2024.
- Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period.
- By disease type insight, the diffuse large B-cell lymphoma (DLBCL) segment held a dominant presence in the market in 2024.
- By disease type insight, the mantle cell lymphoma segment is expected to grow at the fastest rate in the market during the forecast period of 2025 to 2034.
- By end-use insight, the hospital pharmacies segment led the market in 2024.
- By end-use insight, the retail pharmacies segment is expected to grow at the fastest rate during the forecast period.
- By therapy insight, the chemotherapy segment led the U.S. hematologic malignancies market.
- By therapy insight, the immunotherapy segment is set to experience the fastest rate of market growth from 2025 to 2034.
Industry Valuation and Growth Rate Projection
| Industry Worth |
Details |
| Market Size in 2025 |
USD 3.15 Billion |
| Market Size by 2034 |
USD 58.2 Billion |
| Market Growth Rate from 2025 to 2034 |
CAGR of 38.2% |
The U.S. hematologic malignancies market chiefly regards cancers appearing in the blood, bone marrow, and lymphatic systems, which include leukemia, lymphoma, and multiple myeloma. While carcinogenic factors increase cancer cases in cities, the market comes under a bit of pressure. Lifestyle-related diseases have become more epidemic due to the sedentary lifestyle, poor diet, smoking, and alcohol consumption. Leukemia occurs as the most common cancer in children and those below 15 years of age, and lymphoma takes the lead in adults. Therapeutic advances, especially in areas of combination therapy, in one way or the other, have altered the prognosis. The whole idea of personal medicine still remains alive in contemporary days, which is driving the growth of tailored approaches that consider individual profiles of patients.
US Hematologic Malignancies Market: Stats and Figures
- Follicular lymphoma (FL) is a slow-growing yet incurable form of non-Hodgkin lymphoma (NHL), representing approximately 20-25% of NHL cases in the US.
- The average age at diagnosis is 70, and chronic lymphocytic leukemia is rarely seen in those under the age of 40.
- MCL accounts for approximately 5% of all NHL cases in the United States and Europe.
How AI has Benefited the Market
The advantages of artificial intelligence (AI) in the U.S. hematologic malignancies marketplace consist of both avenues where more accurate diagnostic methods have been achieved, treatment timelines have been enhanced, and a separate and personalized treatment approach has been offered. AI tools sift through complex datasets generated from blood smears, bone marrow biopsies, and genomic profiles, picking out subtle changes that traditional methods miss. So, this diagnosis is much faster and made with an acute eye for rare sorts of leukemia, lymphoma, and multiple myeloma. In risk stratification, the AI highlights those at high risk so that clinicians come forward to intervene at an earlier stage. Hence, some individualized treatment options can be developed based on predictions to optimize outcomes while minimizing side effects. And better survival reduces healthcare costs while creating a treatment ecosystem in its best state.
Market Dynamics
What are the Major Market Drivers in the US Hematologic Malignancies Market?
The major market drivers in the U.S. hematologic malignancies market are increasing incidence of blood cancers, rising awareness about early diagnosis, growing adoption of personalized medicine, and an aging population.
- Increasing Incidence of Blood Cancers: Rising incidence of blood cancers like leukemia, lymphoma, and multiple myeloma draws interest in the U.S. hematologic malignancies market. Quite a sizeable percentage of all U.S. cancer diagnoses are constituted by these blood cancers, whose prevalence is slowly but surely escalating. Environmental factors, genetic predispositions, risks related to lifestyle, and better diagnostics are agents of this enlargement. This, in turn, has created a high demand for better diagnostic tools and advanced treatment modes, especially for early detection, being the most vital consideration for survival and arresting disease advancement. Pharmaceutical and biotech companies have been investing a huge amount of R&D budgets in this therapy area for novel therapy modalities such as CAR-T cell therapy, monoclonal antibodies, and small-molecule inhibitors. The rising cases of blood cancers foster therapeutic innovation and lead to further growth in the market, with hospitals, diagnostic laboratories, and ambulatory centers adding hematology services to meet the increasing demand.
- Rising number of aging people: In the wake of changes in the population, the hematologic malignancies market is going upward, with the common diagnoses of leukemia, lymphoma, and multiple myeloma among older people. With a steady increase in average life spans and the percentage of individuals over 65 growing among Americans, it is aptly expected that age-related cancers will render some preference with increased incidence. Immune alteration and hematopoietic-function changes in elderly persons suffice for the easier accumulation of mutations into a malignancy. This underscores that, in the greater age demographic, early-stage diagnosis, periodic screening, and long-term treatment options need to be emphasized.
What are the Major Market Restraints in the US Hematologic Malignancies Market?
The growth of the U.S. hematologic malignancies market is restrained by factors such as limited accessibility in some regions, high treatment costs, lack of skilled professionals.
- Limited accessibility: The landscape of haematological diseases is facing significant impediments in the United States, mostly due to limited access to skilled care and advanced treatments, especially in rural or underserved areas. Remote patients endured long commutes; a handful of providers, a lack of advanced diagnostics, and a lack of appropriate therapeutic infrastructure required for establishing a timely diagnosis and correct treatment. Socioeconomic backwardness, together with the lack of insurance coverage and racial and ethnic disparities, act to place this inequity in situ. The underprivileged and those opting for public insurance do not have access to advanced treatments like CAR-T cell therapy or bone marrow transplantation. Such issues of accessibility and.A3 I'm problems only limit the uncertainty effects of newer therapies and put growth at ransom for the broader market.
- Disease complexity: Hematologic malignancies encompass leukemias, lymphomas, and multiple myelomas that are complicated diseases possessing a variety of subtypes, genetic mutations, and clinical behaviors. Personalized medicine is therefore essential for a successful treatment, yet it subjects research to greater complexities and costs. Patients differ in their treatment responses to therapies, and deterioration in the effectiveness of therapies due to resistance further stymies long-term disease management. Managing relapsed cases is, therefore, becoming increasingly expensive, with access to cutting-edge therapies still not available to all. While this heterogeneity impedes the ability to scale therapies, it equally slows down innovation and, in so doing, affects the manufacturers, the providers of healthcare, and the patients within the market.
What are the Market Opportunities in the US Hematologic Malignancies Market?
The opportunities in the U.S. hematologic malignancies market are associated with advancements in targeted therapies, the rise of immunotherapy, CAR-T cell therapy, and the development of next-generation monoclonal antibodies.
Advancements in Targeted Therapies:
- Targeted therapies represent a worthwhile opportunity that is growing in the U.S. hematologic malignancies market by working against cancer cells with foreign molecular markers or pathways. Such treatments bear an added advantage of becoming highly efficacious with fewer side effects as compared to chemotherapy. Further opened by genomics and molecular biology, which avails treatments for leukemia, lymphoma, and multiple myeloma on a much more precise scale, pharmaceutical companies have now extended their targeted agents pipeline, creating windows for innovation and commercialization.
- Rise of Immunotherapy: Immunotherapy is changing the way hematologic malignancies are treated, with CAR-T cell therapy, checkpoint inhibitors, and bispecific antibodies modifying the course of treatment for relapsed or refractory blood cancers. CAR-T cell therapy has brought a great cure in some leukemias and lymphomas. As more immunotherapies are approved by the FDA with proof of long-term efficacy, their clinical implication will only increase. Reduced costs of production, expanded indications, and further research will position immunotherapy as the lead treatment method for blood cancers shortly.
- Personalized Medicine: Personalized medicine represents an emerging area in the United States hematologic malignancies market, in which physicians can prepare treatment plans for the individual patient depending on genomic, molecular, and biomarker information. With advances in NGS and diagnostics, diseases can be typed down to the last subtype, and mutations can be precisely identified for the application of targeted treatment or immunotherapy. This is highly relevant in multi-faceted malignancies of leukemia and lymphoma. With the decrease in the cost of genetic tests and increasing clinical relevance, the emergence of personalized medicine would, therefore, imply a change in treatment approaches and enhance the market size.
Industry Leader Announcements
- Dr. Xiaolin Zhang, CEO of Dizal:
“We are excited that golidocitinib and DZD8586 have demonstrated promising potential in PTCL and B-cell non-Hodgkin lymphoma (B-NHL), two areas with substantial unmet clinical needs. The selection of multiple studies for oral presentations at global leading conferences represents a strong recognition of our capabilities in research and development and further affirms our commitment to bringing transformative therapies to patients worldwide.”
- Adam Roach, Senior Vice President and Head of Japan and Asia Pacific region for BeiGene:
“The introduction of BRUKINSA in India marks an important step in our ongoing mission to expand patient access to innovative oncology treatments across the Asia Pacific region. We are proud to support Glenmark in bringing this therapy to patients in India, furthering our shared commitment to improve healthcare outcomes globally.”
Segmental Insights
Disease Type Insight
Tthe diffuse large B-cell lymphoma (DLBCL) segment dominated the market in 2024. Diffuse Large B-cell Lymphoma has always been one of the common types of lymphoma and, therefore, any list of hematologic malignancies will place it at the forefront. In fact, increasing incidence, particularly among the elderly, led to demand for chemotherapy, monoclonal antibodies, CAR-T cell therapies, and other solutions, resulting in even collaborative approaches to care that are cost-building. Increasing diagnoses and active targeted treatment approaches continue to place DLBCL as the No. 1 hematologic oncology disease.
The mantle cell lymphoma segment is expected to grow at the fastest CAGR in the market during the forecast period of 2025 to 2034. The aggressive nature of the disease gives it very fast-growing potential in the hematologic malignancies landscape, but it remains rare. Being less common, with its rising prevalence among aging populations, is a motivator for increased R&D activities. It will prompt a change in treatment paradigm from conventional chemotherapy to targeted therapies, immunotherapies, and epigenetic agents, while personalized medicine and diagnostics are assisting in improving outcomes. It is slated to show very rapid growth.
End Use Insight
The hospital pharmacies segment dominated the market in 2024 because hospital pharmacies are internationally considered centers for dispensing hematologic malignancies; they carry out the dispensing of these medications because of the necessity to handle complex treatment regimens needing the preparation and administration of high-risk oncology drugs with close monitoring of the patient during chemotherapy, immunotherapy, or CAR-T treatments. Centralized cancer care, continuous advances in treatment protocols, and diagnostics favor the dispensing of hematologic cancer medicines via hospital pharmacies, especially for newly diagnosed or critically ill patients admitted to hospitals or requiring full hospital support.
The retail pharmacies segment is projected to grow at the fastest CAGR, thanks to the availability of oral medicines for blood cancer, increased awareness, patient preference for easy access, and improved services, including pharmacist consultation and collaborative care models. Retail pharmacies are also ushering in the new era of oncology-supportive services. As treatments become more targeted and less reliant on intravenous administration, retail pharmacies are expected to play a critical role in medication access and adherence.
Therapy Insight
Chemotherapy accounted for the largest market revenue share in 2024. Chemotherapy, being the chief mode of treating hematologic malignancies, thus comes as the cornerstone of therapy for a large number of blood cancers. It is considered to be used in tandem with newer therapies, as research continues to focus on making the case that chemotherapy and targeted therapies together increase efficacy. However, chemotherapy still holds a position of great importance as a complete "all-purpose" fairly fitting into nearly every multi-modal approach of treatment.
Immunotherapy is expected to register the fastest CAGR during the forecast period. Immunotherapy would, thus, soon be established as a cornerstone in the treatment of hematological malignancies. It harnesses the power of an individual's immune system to identify, isolate, and kill their cancer cells. Monoclonal antibodies, CAR-T cell therapy, and immune checkpoint inhibitors are assisting in creating pathways for treatment. Since immunotherapy is currently gaining more indications and regulatory support, this seems to be the treatment of choice for relapsed or refractory cancers.
Recent Developments in the U.S. Hematologic Malignancies Market:
- In June 2025, Dizal, a biopharmaceutical company, will present research findings on its hematologic oncology assets, golidocitinib and DZD8586, at the 2025 EHA Annual Congress and ICML. These include long-term follow-up data on golidocitinib and pooled analysis results for DZD8586. https://www.prnewswire.com/news-releases/dizal-showcases-two-first-in-class-therapies-in-hematologic-malignancies-at-eha-and-icml-2025-302480124.html
- In June 2025, Glenmark Pharmaceuticals plans to launch zanubrutinib in India under the brand BRUKINSA, developed by BeiGene. BRUKINSA is the first and only Bruton's tyrosine kinase inhibitor approved in India for treating five B-cell malignancies. https://www.indianpharmapost.com/news/glenmark-pharmaceuticals-to-launch-dcgi-approved-brukinsa-in-india-for-treatment-of-hematological-malignancies-17261
- In March 2025, Orca Bio reported positive results from its Phase 3 Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with AML, ALL, MDS, and MPAL, using purified regulatory T-cells. https://www.businesswire.com/news/home/20250317038531/en/Orca-Bio-Announces-Positive-Results-from-the-Pivotal-Phase-3-Study-of-Investigational-Orca-T-Compared-to-Allogeneic-Stem-Cell-Transplant-for-the-Treatment-of-Hematologic-Malignancies
Competitive Landscape
The market is moderately fragmented with local players like AbbVie Inc., Amgen Inc., etc., wishing to take the time to edge their presence through investments, partnerships, acquisitions, and mergers. They also invest in product development and competitive pricing. These strategies will promote market growth and lucrative opportunities for market players
- Company Name: AbbVie Inc.
- Year of Incorporation: 2013
- Headquarters: North Chicago, Illinois
AbbVie's most recent annual revenue (TTM) is ₹4.898 trillion. In 2024, the company reported revenue of ₹4.832 trillion, an increase compared to ₹4.521 trillion in 2023.
- Company Name: Amgen Inc.
- Year of Incorporation: 1980
- Headquarters: Thousand Oaks, California
In 2023, the company reported $28.19 billion in revenue, which increased to $33.42 billion in 2024, a 18.57% increase.
- Company Name: Johnson & Johnson
- Year of Incorporation: 1886
- Headquarters: New Brunswick, New Jersey, USA
Johnson & Johnson's (J&J) total revenue for 2024 was $88.82 billion, a 4.3% increase from $85.16 billion in 2023.
US Hematologic Malignancies Market Share, By Disease / Indication, 2024 (%)
| By Disease / Indication |
Shares (%) |
| Acute Lymphoblastic Leukemia (ALL) |
8% |
| Diffuse Large B-cell Lymphoma (DLBCL) |
20% |
| Mantle Cell Lymphoma (MCL) |
4% |
| Follicular Lymphoma (FL) |
9% |
| Multiple Myeloma (MM) |
28% |
| Chronic Lymphocytic Leukemia (CLL) |
14% |
| Hodgkin’s Lymphoma |
5% |
| Other Non-Hodgkin Lymphomas (NHL) |
12% |
- Acute Lymphoblastic Leukemia (ALL) – Holds 8% of the 2024 market, falling to 6.75% by 2034 – Represents a smaller share of hematologic cases. Does not dominate due to comparatively lower incidence and slower therapeutic innovation.
- Diffuse Large B-cell Lymphoma (DLBCL) – Accounts for 20% of the 2024 market, rising to 21.56% by 2034 – A major lymphoma subtype needing intensive and targeted care. Gaining momentum as novel immunotherapies expand and diagnosis rates increase.
- Mantle Cell Lymphoma (MCL) – Holds 4% of the 2024 market, declining to 3.35% by 2034 – A rare and aggressive lymphoma. Does not dominate due to low prevalence and complex treatment pathways.
- Follicular Lymphoma (FL) – Represents 9% of the 2024 market, slipping to 7.95% by 2034 – A slow-growing lymphoma group. Not dominating as incidence rises slowly and therapeutic activity is outpaced by other cancers.
- Multiple Myeloma (MM) – Captures 28% of the 2024 market, surging to 34.16% by 2034 – One of the fastest-growing oncology areas. Dominates and gains momentum due to strong innovation in immunotherapy, CAR-T, and targeted treatments.
- Chronic Lymphocytic Leukemia (CLL) – Holds 14% of the 2024 market, dropping to 12.02% by 2034 – A common leukemia subtype. Losing dominance as generic entry lowers value and other malignancies expand faster.
- Hodgkin’s Lymphoma – Represents 5% of the 2024 market, falling to 4.30% by 2034 – A mature, well-controlled disease category. Does not dominate due to stable incidence and limited commercial expansion.
- Other Non-Hodgkin Lymphomas (NHL) – Accounts for 12% of the 2024 market, slipping to 10.99% by 2034 – A diverse group with varied treatment patterns. Not dominating as priority shifts toward higher-value, high-incidence malignancies.
US Hematologic Malignancies Market Share, By Therapy, 2024 (%)
| Segments |
Shares (%) |
| Chemotherapy |
30% |
| Immunotherapy |
35% |
| Targeted Therapy |
30% |
| Other Therapies |
5% |
- Chemotherapy – Holds 30% of the 2024 market, declining to 19.49% by 2034 – The traditional treatment backbone. Losing dominance as newer targeted and immune-based therapies replace conventional regimens.
- Immunotherapy – Captures 35% of the 2024 market, rising to 44.28% by 2034 – The leading advanced therapy class. Dominates and gains momentum due to breakthrough approvals, strong efficacy, and expanding clinical adoption.
- Targeted Therapy – Represents 30% of the 2024 market, growing to 33.50% by 2034 – Precision-based treatments. Gaining momentum as more indications secure approvals and personalized medicine becomes standard.
- Other Therapies – Accounts for 5% of the 2024 market, shrinking to 2.73% by 2034 – Includes niche or supportive treatments. Does not dominate due to limited therapeutic importance and reduced market investment.
US Hematologic Malignancies Market Share, By End Use, 2024 (%)
| Segments |
Shares (%) |
| Hospital Pharmacies |
70% |
| Retail Pharmacies |
30% |
- Hospital Pharmacies – Holds 70% of the 2024 market, easing to 65.00% by 2034 – The main dispensing channel for high-complexity oncology drugs. Dominates due to the need for supervised administration, though losing some share to outpatient models.
- Retail Pharmacies – Represents 30% of the 2024 market, rising to 35.00% by 2034 – Dispenses oral and self-administered therapies. Gaining momentum as more hematologic cancer treatments transition to convenient at-home use.
